<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:podcast="https://podcastindex.org/namespace/1.0" xmlns:media="http://search.yahoo.com/mrss/" version="2.0"><channel><title>Beta Finch - Danaher - DHR - EN</title><link>https://betafinch.com</link><description><![CDATA[AI-powered earnings call analysis for Danaher (DHR). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.]]></description><atom:link href="https://www.spreaker.com/show/7457633/episodes/feed" rel="self" type="application/rss+xml"/><language>en</language><category>Investing</category><copyright>2026 Beta Finch</copyright><image><url>https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/cc3ff9d21a321407ba555c9f81a41dd0.jpg</url><title>Beta Finch - Danaher - DHR - EN</title><link>https://betafinch.com</link></image><lastBuildDate>Fri, 13 Nov 2026 14:32:20 +0000</lastBuildDate><itunes:author>Beta Finch</itunes:author><itunes:owner><itunes:name>Beta Finch</itunes:name><itunes:email>contact@betafinch.com</itunes:email></itunes:owner><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/cc3ff9d21a321407ba555c9f81a41dd0.jpg"/><itunes:subtitle>AI-powered earnings call analysis for Danaher (DHR). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.</itunes:subtitle><itunes:summary><![CDATA[AI-powered earnings call analysis for Danaher (DHR). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.]]></itunes:summary><itunes:category text="Business"><itunes:category text="Investing"/></itunes:category><itunes:explicit>false</itunes:explicit><podcast:guid>77ea9b16-10e7-5ef1-bd41-c829666b4d3e</podcast:guid><podcast:txt purpose="ai-content">true</podcast:txt><itunes:type>episodic</itunes:type><item><title>Danaher Q3 2026 Earnings Analysis</title><link>https://www.spreaker.com/episode/danaher-q3-2026-earnings-analysis--75906159</link><description><![CDATA[More earnings analysis: <a href="https://betafinch.com" rel="noopener">https://betafinch.com</a><br />──────────<br />**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.<br /><br />**JORDAN:** And I'm Jordan. We've got a big one today — Danaher, ticker DHR, reporting Q3 2026 results, plus a new CEO laying out her vision for the company's "next chapter."<br /><br />**ALEX:** Lots to dig into. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.<br /><br />**JORDAN:** Important stuff, now let's get into it. Alex, this quarter actually beat expectations across the board.<br /><br />**ALEX:** It did. Revenue came in at $6.6 billion. Core revenue growth, excluding respiratory products, was 5.5% — that's a 100 basis point acceleration from Q2. Adjusted EPS was $2.11, up about 11.5% year-over-year. And free cash flow? $1.6 billion in the quarter alone.<br /><br />**JORDAN:** And that cash flow number matters — year-to-date free cash flow to net income conversion was 128%. That's a sign of genuinely high-quality earnings, not just accounting magic.<br /><br />**ALEX:** Right. Now, there's a wrinkle here — respiratory diagnostics, think flu and COVID testing, has been a drag all year because infection rates are just lower than prior years. That category was about a 250 basis point headwind in Q3. Strip that out, and the underlying business is clearly reaccelerating.<br /><br />**JORDAN:** Segment-wise, Biotechnology grew 5%, with bioprocessing — basically equipment and consumables for manufacturing biologic drugs — coming in at the upper end of mid-single digits. Orders there grew mid-teens, which is a really encouraging forward indicator.<br /><br />**ALEX:** Life Sciences grew 4.5%, third straight quarter beating internal expectations. And Diagnostics, excluding respiratory, was up 7%. Beckman Coulter Diagnostics had its best core growth quarter in over two years.<br /><br />**JORDAN:** Geographically, high-growth markets were the story — up about 10%, with China up high-single digits across all three segments. Developed markets were basically flat, with North America dragged down mostly by that respiratory decline.<br /><br />**ALEX:** On guidance — Danaher raised full-year adjusted EPS guidance to $8.57 to $8.62, up from $8.45 to $8.60. Q4 core growth ex-respiratory is expected at 4% to 5%, with operating margin around 29.5%.<br /><br />**JORDAN:** And they gave us an early look at 2027 — suggesting that same 4-5% core growth rate ex-respiratory as a starting point. A few analysts on the call pushed back on that, honestly. Given strong bioprocessing orders, easing China headwinds, and recovering biotech funding, why isn't the number higher?<br /><br />**ALEX:** Yeah, that was Tycho Peterson from Jefferies basically saying "show me the acceleration." Management's answer was essentially: we want to get through our Q4 planning process before committing to anything more specific, formal guidance comes in January.<br /><br />**JORDAN:** Fair, but it does leave a little tension in the air — is this conservatism, or is something softer under the hood? I'd lean toward conservatism given the order trends they's describing, but it's worth watching.<br /><br />**ALEX:** Now let's talk strategy, because this call was really about new CEO Julie Sawyer Montgomery setting her agenda. She's a Danaher veteran — nine years at the company — stepping into the top role for the first time this quarter.<br /><br />**JORDAN:** She laid out four priorities: commercial excellence, innovation, talent, and disciplined capital allocation. The headline message was that Danaher's big portfolio transformation — becoming a pure-play Life Sciences and Diagnostics company — is basically done. Now it's about execution and growth, not reshaping the business.<br /><br />**ALEX:** The phrase that stuck with me was "unambiguous share gain" — she used it multiple times as the real report card for success going forward.<br /><br />**JORDAN<br /><br />This episode includes AI-generated content.]]></description><guid isPermaLink="false">DHR-Q3-2026-en</guid><pubDate>Wed, 21 Oct 2026 22:21:28 +0000</pubDate><enclosure url="https://dts.podtrac.com/redirect.mp3/api.spreaker.com/download/episode/75906159/dhr_2026_q3_fc6389_en.mp3" length="7555244" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/3f41e518-e5ce-4302-a3e3-7897a355e757/3f41e518-e5ce-4302-a3e3-7897a355e757.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/3f41e518-e5ce-4302-a3e3-7897a355e757/3f41e518-e5ce-4302-a3e3-7897a355e757.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/3f41e518-e5ce-4302-a3e3-7897a355e757/3f41e518-e5ce-4302-a3e3-7897a355e757.vtt" type="text/vtt" language="en"/><podcast:txt purpose="ai-content">true</podcast:txt><itunes:author>Beta Finch</itunes:author><itunes:subtitle>More earnings analysis: https://betafinch.com
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.

**JORDAN:** And I'm Jordan. We've got a big one today — Danaher, ticker DHR, reporting Q3 2026 results, plus a new...</itunes:subtitle><itunes:summary><![CDATA[More earnings analysis: <a href="https://betafinch.com" rel="noopener">https://betafinch.com</a><br />──────────<br />**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.<br /><br />**JORDAN:** And I'm Jordan. We've got a big one today — Danaher, ticker DHR, reporting Q3 2026 results, plus a new CEO laying out her vision for the company's "next chapter."<br /><br />**ALEX:** Lots to dig into. But first, our standard disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.<br /><br />**JORDAN:** Important stuff, now let's get into it. Alex, this quarter actually beat expectations across the board.<br /><br />**ALEX:** It did. Revenue came in at $6.6 billion. Core revenue growth, excluding respiratory products, was 5.5% — that's a 100 basis point acceleration from Q2. Adjusted EPS was $2.11, up about 11.5% year-over-year. And free cash flow? $1.6 billion in the quarter alone.<br /><br />**JORDAN:** And that cash flow number matters — year-to-date free cash flow to net income conversion was 128%. That's a sign of genuinely high-quality earnings, not just accounting magic.<br /><br />**ALEX:** Right. Now, there's a wrinkle here — respiratory diagnostics, think flu and COVID testing, has been a drag all year because infection rates are just lower than prior years. That category was about a 250 basis point headwind in Q3. Strip that out, and the underlying business is clearly reaccelerating.<br /><br />**JORDAN:** Segment-wise, Biotechnology grew 5%, with bioprocessing — basically equipment and consumables for manufacturing biologic drugs — coming in at the upper end of mid-single digits. Orders there grew mid-teens, which is a really encouraging forward indicator.<br /><br />**ALEX:** Life Sciences grew 4.5%, third straight quarter beating internal expectations. And Diagnostics, excluding respiratory, was up 7%. Beckman Coulter Diagnostics had its best core growth quarter in over two years.<br /><br />**JORDAN:** Geographically, high-growth markets were the story — up about 10%, with China up high-single digits across all three segments. Developed markets were basically flat, with North America dragged down mostly by that respiratory decline.<br /><br />**ALEX:** On guidance — Danaher raised full-year adjusted EPS guidance to $8.57 to $8.62, up from $8.45 to $8.60. Q4 core growth ex-respiratory is expected at 4% to 5%, with operating margin around 29.5%.<br /><br />**JORDAN:** And they gave us an early look at 2027 — suggesting that same 4-5% core growth rate ex-respiratory as a starting point. A few analysts on the call pushed back on that, honestly. Given strong bioprocessing orders, easing China headwinds, and recovering biotech funding, why isn't the number higher?<br /><br />**ALEX:** Yeah, that was Tycho Peterson from Jefferies basically saying "show me the acceleration." Management's answer was essentially: we want to get through our Q4 planning process before committing to anything more specific, formal guidance comes in January.<br /><br />**JORDAN:** Fair, but it does leave a little tension in the air — is this conservatism, or is something softer under the hood? I'd lean toward conservatism given the order trends they's describing, but it's worth watching.<br /><br />**ALEX:** Now let's talk strategy, because this call was really about new CEO Julie Sawyer Montgomery setting her agenda. She's a Danaher veteran — nine years at the company — stepping into the top role for the first time this quarter.<br /><br />**JORDAN:** She laid out four priorities: commercial excellence, innovation, talent, and disciplined capital allocation. The headline message was that Danaher's big portfolio transformation — becoming a pure-play Life Sciences and Diagnostics company — is basically done. Now it's...]]></itunes:summary><itunes:duration>473</itunes:duration><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/cc3ff9d21a321407ba555c9f81a41dd0.jpg"/><itunes:episodeType>full</itunes:episodeType></item><item><title>Coming Soon: Danaher (DHR) Earnings Analysis</title><link>https://www.spreaker.com/episode/coming-soon-danaher-dhr-earnings-analysis--75739757</link><description><![CDATA[Beta Finch's AI-powered earnings call analysis for Danaher (DHR) is coming soon. Follow the show to get the first full episode as soon as Danaher reports.<br /><br />This episode includes AI-generated content.]]></description><guid isPermaLink="false">https://api.spreaker.com/episode/75739757</guid><pubDate>Tue, 13 Oct 2026 02:03:31 +0000</pubDate><enclosure url="https://dts.podtrac.com/redirect.mp3/api.spreaker.com/download/episode/75739757/coming_soon_en.mp3" length="1933104" type="audio/mpeg"/><podcast:transcript url="https://transcription.spreaker.com/starship/8876eea1-d1f3-451e-84f2-b8d0f7a7c580/8876eea1-d1f3-451e-84f2-b8d0f7a7c580.srt" type="application/x-subrip" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/8876eea1-d1f3-451e-84f2-b8d0f7a7c580/8876eea1-d1f3-451e-84f2-b8d0f7a7c580.txt" type="text/plain" language="en"/><podcast:transcript url="https://transcription.spreaker.com/starship/8876eea1-d1f3-451e-84f2-b8d0f7a7c580/8876eea1-d1f3-451e-84f2-b8d0f7a7c580.vtt" type="text/vtt" language="en"/><podcast:txt purpose="ai-content">true</podcast:txt><itunes:author>Beta Finch</itunes:author><itunes:subtitle>Beta Finch's AI-powered earnings call analysis for Danaher (DHR) is coming soon. Follow the show to get the first full episode as soon as Danaher reports.</itunes:subtitle><itunes:summary><![CDATA[Beta Finch's AI-powered earnings call analysis for Danaher (DHR) is coming soon. Follow the show to get the first full episode as soon as Danaher reports.<br /><br />This episode includes AI-generated content.]]></itunes:summary><itunes:duration>121</itunes:duration><itunes:explicit>false</itunes:explicit><itunes:image href="https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/cc3ff9d21a321407ba555c9f81a41dd0.jpg"/><itunes:episodeType>full</itunes:episodeType></item></channel></rss>
